Advertisement

Molecular Medicine

, Volume 17, Issue 1–2, pp 113–125 | Cite as

Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies

  • Gerd G. Gauglitz
  • Hans C. Korting
  • Tatiana Pavicic
  • Thomas Ruzicka
  • Marc G. Jeschke
Review Article

Abstract

Excessive scars form as a result of aberrations of physiologic wound healing and may arise following any Insult to the deep dermis. By causing pain, pruritus and contractures, excessive scarring significantly affects the patient’s quality of life, both physically and psychologically. Multiple studies on hypertrophic scar and keloid formation have been conducted for decades and have led to a plethora of therapeutic strategies to prevent or attenuate excessive scar formation. However, most therapeutic approaches remain clinically unsatisfactory, most likely owing to poor understanding of the complex mechanisms underlying the processes of scarring and wound contraction. In this review we summarize the current understanding of the pathophysiology underlying keloid and hypertrophic scar formation and discuss established treatments and novel therapeutic strategies.

References

  1. 1.
    Sund B. (2000) New Developments in Wound Care. PJB Publications, London, pp. 1–255.Google Scholar
  2. 2.
    Berman B, Bieley HC. (1995) Keloids. J. Am. Acad. Dermatol. 33:117–23.PubMedCrossRefGoogle Scholar
  3. 3.
    Peacock EE Jr, Madden JW, Trier WC. (1970) Biologic basis for the treatment of keloids and hypertrophic scars. South. Med. J. 63:755–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Mancini RE, Quaife JV. (1962) Histogenesis of experimentally produced keloids. J. Invest. Dermatol. 38:143–81.PubMedCrossRefGoogle Scholar
  5. 5.
    Atiyeh BS. (2007) Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic. Plast. Surg. 31:468–94.PubMedCrossRefGoogle Scholar
  6. 6.
    Slemp AE, Kirschner RE. (2006) Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr. Opin. Pediatr. 18:396–402.PubMedCrossRefGoogle Scholar
  7. 7.
    Wheeland RG. (1996) Keloids and hypertrphic scars. In: Cutaneous Medicine and Surgery. Arndt KA, Robinson JK, Leboit PE, Wintroub BU (eds.). Saunders Elsevier, Philadelphia, pp. 900–5.Google Scholar
  8. 8.
    Alster TS, West TB. (1997) Treatment of scars: a review. Ann. Plast. Surg. 39:418–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Hawkins HK. (2007) Pathophysiology of the burn scar. In: Total Burn Care. Herndon DN (ed.) Saunders Elsevier, Philadelphia, pp. 608–19.CrossRefGoogle Scholar
  10. 10.
    Murray JC. (1994) Keloids and hypertrophic scars. Clin. Dermatol. 12:27–37.PubMedCrossRefGoogle Scholar
  11. 11.
    Al-Attar A, et al. (2006) Keloid pathogenesis and treatment. Plast. Reconstr. Surg. 117:286–300.PubMedCrossRefGoogle Scholar
  12. 12.
    From L, Assad D. (1993) Neoplasms, pseudoneoplasms, and hyperplasia of supporting tissue origin. In: Dermatology in General Medicine. Jeffers JD, Englis MR (eds.). McGraw-Hill, New York, pp. 1198–99.Google Scholar
  13. 13.
    Muir IF. (1990) On the nature of keloid and hypertrophic scars. Br. J. Plast. Surg. 43:61–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Niessen FB, Spauwen PH, Schalkwijk J, Kon M. (1999) On the nature of hypertrophic scars and keloids: a review. Plast. Reconstr. Surg. 104:1435–58.PubMedCrossRefGoogle Scholar
  15. 15.
    Leventhal D, Furr M, Reiter D. (2006) Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch. Facial. Plast. Surg. 8:362–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Sephel GC, Woodward SC. (2001) Repair, regeneration, and fibrosis. In: Rubin’s Pathology. Rubin E (ed.). Lippincott, Williams & Wilkins, Baltimore, pp. 84–117.Google Scholar
  17. 17.
    Oluwasanmi JO. (1974) Keloids in the African. Clin. Plast. Surg. 1:179–95.PubMedGoogle Scholar
  18. 18.
    Moustafa MF, Abdel-Fattah MA, Abdel-Fattah DC. (1975) Presumptive evidence of the effect of pregnancy estrogens on keloid growth: case report. Plast. Reconstr. Surg. 56:450–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Deitch EA, et al. (1983) Hypertrophic burn scars: analysis of variables. J. Trauma. 23:895–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Lewis WH, Sun KK. (1990) Hypertrophic scar: a genetic hypothesis. Burns. 16:176–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Murray CJ, Pinnel SR. (1992) Keloids and excessive dermal scarring. In: Woundhealing, Biochemical and Clinical Aspects. Cohen IK, Diegelmann RF, Lindblad WJ (eds.). Saunders Elsevier, Philadelphia, pp. 500–9.Google Scholar
  22. 22.
    Bayat A, et al. (2005) Keloid disease: clinical relevance of single versus multiple site scars. Br. J. Plast. Surg. 58:28–37.PubMedCrossRefGoogle Scholar
  23. 23.
    Marneros AG, et al. (2004) Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J. Invest. Dermatol. 122:1126–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Brown JJ, Ollier WE, Thomson W, Bayat A. (2008) Positive association of HLA-DRB1*15 with keloid disease in Caucasians. Int. J. Immunogenet. 35:303–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Ford LC, King DF, Lagasse LD, Newcomer V. (1983) Increased androgen binding in keloids: a preliminary communication. J. Dermatol. Surg. Oncol. 9:545–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Schierle HP, Scholz D, Lemperle G. (1997) Elevated levels of testosterone receptors in keloid tissue: an experimental investigation. Plast. Reconstr. Surg. 100:390–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Placik OJ, Lewis VL Jr. (1992) Immunologic associations of keloids. Surg. Gynecol. Obstet. 175:185–93.PubMedGoogle Scholar
  28. 28.
    Smith CJ, Smith JC, Finn MC. (1987) The possible role of mast cells (allergy) in the production of keloid and hypertrophic scarring. J. Burn Care Rehabil. 8:126–31.PubMedCrossRefGoogle Scholar
  29. 29.
    Ramakrishnan KM, Thomas KP, Sundararajan CR. (1974) Study of 1,000 patients with keloids in South India. Plast. Reconstr. Surg. 53:276–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Tredget EE, Nedelec B, Scott PG, Ghahary A. (1997) Hypertrophic scars, keloids, and contractures: the cellular and molecular basis for therapy. Surg. Clin. North Am. 77:701–30.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Brown JJ, Bayat A. (2009) Genetic susceptibility to raised dermal scarring. Br. J. Dermatol. 161:8–18.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Armour A, Scott PG, Tredget EE. (2007) Cellular and molecular pathology of HTS: basis for treatment. Wound Repair Regen. 15 Suppl 1:S6–17.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Wynn TA. (2004) Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4:583–94.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Doucet C, et al. (1998) Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J. Clin. Invest. 101:2129–39.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Kamp DW. (2003) Idiopathic pulmonary fibrosis: the inflammation hypothesis revisited. Chest. 124:1187–90.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Ladak A, Tredget EE. (2009) Pathophysiology and management of the burn scar. Clin. Plast. Surg. 36:661–74.PubMedCrossRefGoogle Scholar
  37. 37.
    Butler PD, Longaker MT, Yang GP. (2008) Current progress in keloid research and treatment. J. Am. Coll. Surg. 206:731–41.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Ishihara H, et al. (2000) Keloid fibroblasts resist ceramide-induced apoptosis by overexpression of insulin-like growth factor I receptor. J. Invest. Dermatol. 115:1065–71.PubMedCrossRefGoogle Scholar
  39. 39.
    Tuan TL, Nichter LS. (1998) The molecular basis of keloid and hypertrophic scar formation. Mol. Med. Today. 4:19–24.PubMedCrossRefGoogle Scholar
  40. 40.
    Smith JC, et al. (2008) Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. J. Invest. Dermatol. 128:1298–310.PubMedCrossRefGoogle Scholar
  41. 41.
    Bullard KM, Longaker MT, Lorenz HP. (2003) Fetal wound healing: current biology. World J. Surg. 27:54–61.PubMedCrossRefGoogle Scholar
  42. 42.
    Szulgit G, et al. (2002) Alterations in fibroblast alpha1beta1 integrin collagen receptor expression in keloids and hypertrophic scars. J. Invest. Dermatol. 118:409–15.PubMedCrossRefGoogle Scholar
  43. 43.
    Kose O, Waseem A. (2008) Keloids and hypertrophic scars: are they two different sides of the same coin? Dermatol. Surg. 34:336–46.PubMedGoogle Scholar
  44. 44.
    Bock O, et al. (2005) Studies of transforming growth factors beta 1–3 and their receptors I and II in fibroblast of keloids and hypertrophic scars. Acta. Derm. Venereol. 85:216–20.PubMedGoogle Scholar
  45. 45.
    Schmid P, et al. (1998) Enhanced expression of transforming growth factor-beta type I and type II receptors in wound granulation tissue and hypertrophic scar. Am. J. Pathol. 152:485–93.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Lee TY, et al. (1999) Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann. Plast. Surg. 43:179–84.PubMedGoogle Scholar
  47. 47.
    Xia W, et al. (2004) Complex epithelial-mesenchymal interactions modulate transforming growth factor-beta expression in keloid-derived cells. Wound Repair Regen. 12:546–56.PubMedCrossRefGoogle Scholar
  48. 48.
    Lu L, et al. (2005) The temporal effects of anti-TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J. Am. Coll. Surg. 201:391–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Cordeiro MF, et al. (2003) Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther. 10:59–71.PubMedCrossRefGoogle Scholar
  50. 50.
    Shah M, Foreman DM, Ferguson MW. (1992) Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet. 339:213–4.PubMedCrossRefGoogle Scholar
  51. 51.
    Shah M, Foreman DM, Ferguson MW. (1995) Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J. Cell. Sci. 108(Pt 3):985–1002.PubMedGoogle Scholar
  52. 52.
    Cutroneo KR. (2007) TGF-beta-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen. 15 Suppl 1: S54–60.PubMedCrossRefGoogle Scholar
  53. 53.
    ten Dijke P, Hill CS. (2004) New insights into TGF-beta-Smad signalling. Trends Biochem. Sci. 29:265–73.PubMedCrossRefGoogle Scholar
  54. 54.
    Kopp J, et al. (2005) Abrogation of transforming growth factor-beta signaling by SMAD7 inhibits collagen gel contraction of human dermal fibroblasts. J. Biol. Chem. 280:21570–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Wang Z, et al. (2007) Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. J. Plast. Reconstr. Aesthet. Surg. 60:1193–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Nakao A, et al. (1997) Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature. 389:631–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Dooley S, et al. (2003) Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology. 125:178–91.PubMedCrossRefGoogle Scholar
  58. 58.
    Chen MA, Davidson TM. (2005) Scar management: prevention and treatment strategies. Curr. Opin. Otolaryngol. Head Neck Surg. 13:242–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Terada Y, et al. (2002) Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int. 61: S94–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Niessen FB, Schalkwijk J, Vos H, Timens W. (2004) Hypertrophic scar formation is associated with an increased number of epidermal Langerhans cells. J. Pathol. 202:121–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Andriessen MP, Niessen FB, Van de Kerkhof PC, Schalkwijk J. (1998) Hypertrophic scarring is associated with epidermal abnormalities: an immunohistochemical study. J. Pathol. 186:192–200.PubMedCrossRefGoogle Scholar
  62. 62.
    Lim IJ, et al. (2001) Investigation of the influence of keloid-derived keratinocytes on fibroblast growth and proliferation in vitro. Plast. Reconstr. Surg. 107:797–808.PubMedCrossRefGoogle Scholar
  63. 63.
    Eming SA, Krieg T, Davidson JM. (2007) Inflammation in wound repair: molecular and cellular mechanisms. J. Invest. Dermatol. 127:514–25.PubMedCrossRefGoogle Scholar
  64. 64.
    Moyer KE, Saggers GC, Ehrlich HP. (2004) Mast cells promote fibroblast populated collagen lattice contraction through gap junction intercellular communication. Wound Repair. Regen. 12:269–75.PubMedCrossRefGoogle Scholar
  65. 65.
    Noli C, Miolo A. (2001) The mast cell in wound healing. Vet. Dermatol. 12:303–13.PubMedCrossRefGoogle Scholar
  66. 66.
    Ghahary A, Ghaffari A. (2007) Role of keratinocyte-fibroblast cross-talk in development of hyper-trophic scar. Wound Repair Regen. 15 Suppl 1: S46–53.CrossRefGoogle Scholar
  67. 67.
    Ghahary A, et al. (1996) Collagenase production is lower in post-burn hypertrophic scar fibroblasts than in normal fibroblasts and is reduced by insulin-like growth factor-1. J. Invest. Dermatol. 106:476–81.PubMedCrossRefGoogle Scholar
  68. 68.
    Birkedal-Hansen H, et al. (1993) Matrix metalloproteinases: a review. Crit. Rev. Oral. Biol. Med. 4:197–250.PubMedCrossRefGoogle Scholar
  69. 69.
    Johnson-Wint B. (1988) Do keratinocytes regulate fibroblast collagenase activities during morphogenesis? Ann. N. Y. Acad. Sci. 548:167–73.PubMedCrossRefGoogle Scholar
  70. 70.
    Fujiwara M, Muragaki Y, Ooshima A. (2005) Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. Br. J. Dermatol. 153:295–300.PubMedCrossRefGoogle Scholar
  71. 71.
    Neely AN, et al. (1999) Gelatinase activity in keloids and hypertrophic scars. Wound Repair Regen. 7:166–71.PubMedCrossRefGoogle Scholar
  72. 72.
    Mauviel A. (1993) Cytokine regulation of metalloproteinase gene expression. J. Cell. Biochem. 53:288–95.PubMedCrossRefGoogle Scholar
  73. 73.
    Zhang Y, McCluskey K, Fujii K, Wahl LM. (1998) Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J. Immunol. 161:3071–6.PubMedGoogle Scholar
  74. 74.
    McQuibban GA, et al. (2002) Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood. 100:1160–7.Google Scholar
  75. 75.
    McQuibban GA, et al. (2000) Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 289:1202–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Scott PG, et al. (1996) Chemical characterization and quantification of proteoglycans in human post-burn hypertrophic and mature scars. Clin. Sci. (Lond). 90:417–25.CrossRefGoogle Scholar
  77. 77.
    Sayani K, et al. (2000) Delayed appearance of decorin in healing burn scars. Histopathology. 36:262–72.PubMedCrossRefGoogle Scholar
  78. 78.
    Zhang Z, et al. (2009) Recombinant human decorin inhibits TGF-beta1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. Burns. 35:527–37.PubMedCrossRefGoogle Scholar
  79. 79.
    Mukhopadhyay A, et al. (2010) Syndecan-2 and decorin: proteoglycans with a difference—implications in keloid pathogenesis. J. Trauma. 68:999–1008.PubMedCrossRefGoogle Scholar
  80. 80.
    Nedelec B, et al. (2001) Myofibroblasts and apoptosis in human hypertrophic scars: the effect of interferon-alpha2b. Surgery. 130:798–808.PubMedCrossRefGoogle Scholar
  81. 81.
    Bond JS, et al. (2008) Maturation of the human scar: an observational study. Plast. Reconstr. Surg. 121:1650–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Bond JS, et al. (2008) Scar redness in humans: how long does it persist after incisional and excisional wounding? Plast. Reconstr. Surg. 121:487–96.PubMedCrossRefGoogle Scholar
  83. 83.
    Mustoe TA, et al. (2002) International clinical recommendations on scar management. Plast. Reconstr. Surg. 110:560–71.PubMedCrossRefGoogle Scholar
  84. 84.
    Durani P, Bayat A. (2008) Levels of evidence for the treatment of keloid disease. J. Plast. Reconstr. Aesthet. Surg. 61:4–17.PubMedCrossRefGoogle Scholar
  85. 85.
    Mutalik S. (2005) Treatment of keloids and hypertrophic scars. Indian J. Dermatol. Venereol. Leprol. 71:3–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Baur PS, et al. (1976) Ultrastructural analysis of pressure-treated human hypertrophic scars. J. Trauma. 16:958–67.PubMedCrossRefGoogle Scholar
  87. 87.
    Macintyre L, Baird M. (2006) Pressure garments for use in the treatment of hypertrophic scars—a review of the problems associated with their use. Burns. 32:10–5.PubMedCrossRefGoogle Scholar
  88. 88.
    Kelly AP. (2004) Medical and surgical therapies for keloids. Dermatol. Ther. 17:212–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Reno F, et al. (2003) In vitro mechanical compression induces apoptosis and regulates cytokines release in hypertrophic scars. Wound Repair Regen. 11:331–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Van den Kerckhove E, et al. (2005) The assessment of erythema and thickness on burn related scars during pressure garment therapy as a preventive measure for hypertrophic scarring. Burns. 31:696–702.PubMedCrossRefGoogle Scholar
  91. 91.
    Sawada Y, Sone K. (1992) Hydration and occlusion treatment for hypertrophic scars and keloids. Br. J. Plast. Surg. 45:599–603.PubMedCrossRefGoogle Scholar
  92. 92.
    Fulton JE, Jr. (1995) Silicone gel sheeting for the prevention and management of evolving hypertrophic and keloid scars. Dermatol. Surg. 21:947–51.PubMedGoogle Scholar
  93. 93.
    Reish RG, Eriksson E. (2008) Scar treatments: preclinical and clinical studies. J. Am. Coll. Surg. 206:719–30.PubMedCrossRefGoogle Scholar
  94. 94.
    Phan TT, et al. (2003) Quercetin inhibits fibronectin production by keloid-derived fibroblasts. Implication for the treatment of excessive scars. J. Dermatol. Sci. 33:192–4.PubMedCrossRefGoogle Scholar
  95. 95.
    Jackson BA, Shelton AJ. (1999) Pilot study evaluating topical onion extract as treatment for postsurgical scars. Dermatol. Surg. 25:267–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Chung VQ, Kelley L, Marra D, Jiang SB. (2006) Onion extract gel versus petrolatum emollient on new surgical scars: prospective double-blinded study. Dermatol. Surg. 32:193–7.PubMedGoogle Scholar
  97. 97.
    Beuth J, et al. (2006) Safety and efficacy of local administration of contractubex to hypertrophic scars in comparison to corticosteroid treatment. Results of a multicenter, comparative epidemiological cohort study in Germany. In Vivo. 20:277–83.PubMedGoogle Scholar
  98. 98.
    Ho WS, Ying SY, Chan PC, Chan HH. (2006) Use of onion extract, heparin, allantoin gel in prevention of scarring in Chinese patients having laser removal of tattoos: a prospective randomized controlled trial. Dermatol. Surg. 32:891–6.PubMedGoogle Scholar
  99. 99.
    Asilian A, Darougheh A, Shariati F. (2006) New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol. Surg. 32:907–15.PubMedGoogle Scholar
  100. 100.
    Zurada JM, Kriegel D, Davis IC. (2006) Topical treatments for hypertrophic scars. J. Am. Acad. Dermatol. 55:1024–31.PubMedCrossRefGoogle Scholar
  101. 101.
    Berman B, Kaufman J. (2002) Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J. Am. Acad. Dermatol. 47:S209–11.PubMedCrossRefGoogle Scholar
  102. 102.
    Berman B, et al. (2009) Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study. J. Drugs Dermatol. 8:455–8.PubMedGoogle Scholar
  103. 103.
    Prado A, Andrades P, Benitez S, Umana M. (2005) Scar management after breast surgery: preliminary results of a prospective, randomized, and double-blind clinical study with aldara cream 5% (imiquimod). Plast. Reconstr. Surg. 115:966–72.PubMedCrossRefGoogle Scholar
  104. 104.
    Ferguson MW, et al. (2009) Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet. 373:1264–74.CrossRefGoogle Scholar
  105. 105.
    Bush J, et al. (2010) Therapies with emerging evidence of efficacy: avotermin for the improvement of scarring. Dermatol Res Pract 2010:690613.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Jalali M, Bayat A. (2007) Current use of steroids in management of abnormal raised skin scars. Surgeon. 5:175–80.PubMedCrossRefGoogle Scholar
  107. 107.
    Cruz NI, Korchin L. (1994) Inhibition of human keloid fibroblast growth by isotretinoin and triamcinolone acetonide in vitro. Ann. Plast. Surg. 33:401–5.PubMedCrossRefGoogle Scholar
  108. 108.
    Boyadjiev C, Popchristova E, Mazgalova J. (1995) Histomorphologic changes in keloids treated with Kenacort. J. Trauma. 38:299–302.PubMedCrossRefGoogle Scholar
  109. 109.
    Robles DT, Berg D. (2007) Abnormal wound healing: keloids. Clin. Dermatol. 25:26–32.PubMedCrossRefGoogle Scholar
  110. 110.
    Lawrence WT. (1991) In search of the optimal treatment of keloids: report of a series and a review of the literature. Ann. Plast. Surg. 27:164–78.PubMedCrossRefGoogle Scholar
  111. 111.
    Boutli-Kasapidou F, Tsakiri A, Anagnostou E, Mourellou O. (2005) Hypertrophic and keloidal scars: an approach to polytherapy. Int. J. Dermatol. 44:324–7.PubMedCrossRefGoogle Scholar
  112. 112.
    Jaros E, Priborsky J, Klein L. (1999) Treatment of keloids and hypertrophic scars with cryotherapy [in Czech]. Acta Medica (Hradec Kralove). Suppl. 42:61–3.Google Scholar
  113. 113.
    Yosipovitch G, et al. (2001) A comparison of the combined effect of cryotherapy and corticosteroid injections versus corticosteroids and cryotherapy alone on keloids: a controlled study. J. Dermatolog. Treat. 12:87–90.PubMedCrossRefGoogle Scholar
  114. 114.
    Sharpe D. (1997) Of apples and oranges, file drawers and garbage: why validity issues in meta-analysis will not go away. Clin. Psychol. Rev. 17:881–901.PubMedCrossRefGoogle Scholar
  115. 115.
    Rusciani L, Rossi G, Bono R. (1993) Use of cryotherapy in the treatment of keloids. J. Dermatol. Surg. Oncol. 19:529–34.PubMedCrossRefGoogle Scholar
  116. 116.
    Zouboulis CC, Blume U, Buttner P, Orfanos CE. (1993) Outcomes of cryosurgery in keloids and hypertrophic scars: a prospective consecutive trial of case series. Arch. Dermatol. 129:1146–51.PubMedCrossRefGoogle Scholar
  117. 117.
    Har-Shai Y, Amar M, Sabo E. (2003) Intralesional cryotherapy for enhancing the involution of hypertrophic scars and keloids. Plast. Reconstr. Surg. 111:1841–52.PubMedCrossRefGoogle Scholar
  118. 118.
    Poochareon VN, Berman B. (2003) New therapies for the management of keloids. J. Craniofac. Surg. 14:654–7.PubMedCrossRefGoogle Scholar
  119. 119.
    Zuber TJ, DeWitt DE. (1994) Earlobe keloids. Am. Fam. Physician. 49:1835–41.PubMedGoogle Scholar
  120. 120.
    Guix B, et al. (2001) Treatment of keloids by high-dose-rate brachytherapy: a seven-year study. Int. J. Radiat. Oncol. Biol. Phys. 50:167–72.PubMedCrossRefGoogle Scholar
  121. 121.
    Ogawa R, Mitsuhashi K, Hyakusoku H, Miyashita T. (2003) Postoperative electron-beam irradiation therapy for keloids and hyper-trophic scars: retrospective study of 147 cases followed for more than 18 months. Plast. Reconstr. Surg. 111:547–55.PubMedGoogle Scholar
  122. 122.
    Apfelberg DB, et al. (1984) Preliminary results of argon and carbon dioxide laser treatment of keloid scars. Lasers Surg. Med. 4:283–90.PubMedCrossRefGoogle Scholar
  123. 123.
    Alster TS, Handrick C. (2000) Laser treatment of hypertrophic scars, keloids, and striae. Semin. Cutan. Med. Surg. 19:287–92.PubMedCrossRefGoogle Scholar
  124. 124.
    Tanzi EL, Alster TS. (2004) Laser treatment of scars. Skin Therapy Lett. 9:4–7.PubMedGoogle Scholar
  125. 125.
    Alster T. (2003) Laser scar revision: comparison study of 585-nm pulsed dye laser with and without intralesional corticosteroids. Dermatol. Surg. 29:25–9.PubMedGoogle Scholar
  126. 126.
    Alster TS, Williams CM. (1995) Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet. 345:1198–200.PubMedCrossRefGoogle Scholar
  127. 127.
    Dierickx C, Goldman MP, Fitzpatrick RE. (1995) Laser treatment of erythematous/hypertrophic and pigmented scars in 26 patients. Plast. Reconstr. Surg. 95:84–92.PubMedCrossRefGoogle Scholar
  128. 128.
    Chan HH, et al. (2004) The use of pulsed dye laser for the prevention and treatment of hyper-trophic scars in Chinese persons. Dermatol. Surg. 30:987–94.PubMedCrossRefGoogle Scholar
  129. 129.
    Fiskerstrand EJ, Svaasand LO, Volden G. (1998) Pigmentary changes after pulsed dye laser treatment in 125 northern European patients with port wine stains. Br. J. Dermatol. 138:477–9.PubMedCrossRefGoogle Scholar
  130. 130.
    Hermanns JF, Petit L, Hermanns-Le T, Pierard GE. (2001) Analytic quantification of phototype-related regional skin complexion. Skin. Res. Technol. 7:168–71.PubMedCrossRefGoogle Scholar
  131. 131.
    Jimenez SA, Freundlich B, Rosenbloom J. (1984) Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J. Clin. Invest. 74:1112–6.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Berman B, Duncan MR. (1989) Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J. Am. Acad. Dermatol. 21:694–702.PubMedCrossRefGoogle Scholar
  133. 133.
    Tredget EE, et al. (1998) Transforming growth factor-beta in thermally injured patients with hyper-trophic scars: effects of interferon alpha-2b. Plast. Reconstr. Surg. 102:1317–28; discussion 1329–30.PubMedCrossRefGoogle Scholar
  134. 134.
    Tredget EE, et al. (1998) Transforming growth factor-beta in thermally injured patients with hypertrophic scars: effects of interferon alpha-2b. Plast. Reconstr. Surg. 102:1317–30.PubMedCrossRefGoogle Scholar
  135. 135.
    Espana A, Solano T, Quintanilla E. (2001) Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol. Surg. 27:23–7.PubMedGoogle Scholar
  136. 136.
    Bodokh I, Brun P. (1996) Treatment of keloid with intralesional bleomycin [in French]. Ann. Dermatol. Venereol. 123:791–4.PubMedGoogle Scholar
  137. 137.
    Naeini FF, Najafian J, Ahmadpour K. (2006) Bleomycin tattooing as a promising therapeutic modality in large keloids and hypertrophic scars. Dermatol. Surg. 32:1023–30.PubMedGoogle Scholar
  138. 138.
    Saray Y, Gulec AT. (2005) Treatment of keloids and hypertrophic scars with dermojet injections of bleomycin: a preliminary study. Int. J. Dermatol. 44:777–84.PubMedCrossRefGoogle Scholar
  139. 139.
    Apikian M, Goodman G. (2004) Intralesional 5-fluorouracil in the treatment of keloid scars. Australas. J. Dermatol. 45:140–3.PubMedCrossRefGoogle Scholar
  140. 140.
    Fitzpatrick RE. (1999) Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol. Surg. 25:224–32.PubMedCrossRefGoogle Scholar
  141. 141.
    Nanda S, Reddy BS. (2004) Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol. Surg. 30:54–7.PubMedGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  • Gerd G. Gauglitz
    • 1
    • 2
  • Hans C. Korting
    • 1
  • Tatiana Pavicic
    • 1
  • Thomas Ruzicka
    • 1
  • Marc G. Jeschke
    • 2
    • 3
    • 4
    • 5
  1. 1.Department of Dermatology and AllergologyLudwig Maximilians UniversityMunichGermany
  2. 2.Shriners Hospitals for Children, Department of SurgeryUniversity Texas Medical BranchGalvestonUSA
  3. 3.Ross Tilley Burn CentreSunnybrook Health Sciences CentreTorontoCanada
  4. 4.Sunnybrook Research InstituteSunnybrook Health Sciences CentreTorontoCanada
  5. 5.Department of Surgery, Division of Plastic SurgeryUniversity of TorontoTorontoCanada

Personalised recommendations